FDA Approves Nasal Spray for Treatment-Resistant Depression

Last week, the US Food and Drug Administration (FDA) announced approval of Spravato (esketamine) nasal spray for the treatment of treatment-resistant depression in adults. Spravato is approved for use in conjunction with oral antidepressants.

To be considered treatment-resistant, a person must have tried at least two other types of antidepressant medication without benefit. It is estimated that more than 16 million adults in the United States have experienced at least one major depressive episode. According to the National Institute of Mental Healthand 1 in 3 of them did not respond to at least two different antidepressants.

β€œIt is exciting that the US Food and Drug Administration has approved the use of esketamine to treat treatment-resistant depression,” he says Atsushi Kamiya, MD, PhDassistant professor of psychiatry and behavioral sciences at Johns Hopkins Medicine in Baltimore.

RELATED: Is Ketamine Depression the Best New Hope?

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button